HERCEPTIN 120 mg/ml Solution For Injection 120 mg/ml Solution for injection 5ml Vial

Product Overview

HERCEPTIN 120 mg/ml Solution For Injection is a targeted therapy from Roche, specifically designed to treat certain types of HER2-positive cancers. As a humanized monoclonal antibody, it works by precisely targeting and blocking the human epidermal growth factor receptor 2 (HER2), a protein that plays a key role in cell growth and is found in high amounts on the surface of some cancer cells. This critical medication is widely recognized and utilized across leading pharmaceutical platforms such as Nahdi Online, as well as e-commerce sites like and , signifying its importance in comprehensive cancer treatment regimens.

Benefits of Use

• Specifically targets HER2-positive cancer cells, minimizing harm to healthy cells.
• Significantly improves progression-free survival and overall survival in patients with HER2-positive breast cancer and gastric cancer.
• Reduces the risk of cancer recurrence in early-stage HER2-positive breast cancer.
• Can be used alone or in combination with chemotherapy, depending on the specific cancer type and stage.

How to Use

1. HERCEPTIN 120 mg/ml Solution For Injection is exclusively administered by a qualified healthcare professional.
2. It is given as an intravenous (IV) infusion, meaning the solution is slowly injected into a vein under medical supervision.
3. The precise dosing regimen, which includes an initial loading dose followed by maintenance doses, and its frequency will be carefully determined by your doctor. This determination is based on your body weight, overall medical condition, and the specific type and stage of cancer being treated.
4. Prior to administration, the solution must be meticulously inspected by the healthcare professional for any particulate matter or discoloration to ensure its integrity.
5. Patients should under no circumstances attempt to self-administer this medication due to its specialized nature and administration requirements.

Caution & Warnings

• Cardiotoxicity: HERCEPTIN carries a risk of causing heart problems, including both symptomatic and asymptomatic declines in cardiac function. Regular and thorough cardiac monitoring is therefore essential throughout treatment.
• Pulmonary Toxicity: Serious lung problems, such as shortness of breath and fluid accumulation in the lungs, have been reported in some patients. Prompt medical attention is required if these symptoms occur.
• Infusion Reactions: Patients may experience infusion-related reactions during or shortly after administration, which can range from mild to severe. These may include fever, chills, nausea, vomiting, pain, headache, dizziness, and rash.
• Embryo-Fetal Toxicity: HERCEPTIN can cause significant harm to a fetus if administered to a pregnant woman. It is critical that effective contraception methods are used during the entire course of treatment and for at least 7 months after the final dose.
• Not for Intravitreal Use: This product is strictly intended for intravenous infusion only and must not be administered via any other routes, including intravitreal injection.
• This medication must only be administered and managed under the direct supervision of a physician who is highly experienced in oncology treatment and the management of cancer therapies.

Ingredients

Active Ingredient: Trastuzumab (120 mg/ml). Other Ingredients: L-histidine, L-histidine hydrochloride monohydrate, α,α-trehalose dihydrate, polysorbate 20, and water for injection.

Product Details

Product Name: HERCEPTIN 120 mg/ml Solution For Injection 5ml Vial Brand: HERCEPTIN Manufacturer: Roche Strength: 120 mg/ml Volume: 5ml per vial Dosage Form: Solution for Injection Administration Route: Intravenous Storage: Refrigerate (2°C - 8°C)